Edwards Lifesciences CorporationEWNYSE
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
-1.35%
↓ 135% below average
Average (39q)
3.79%
Historical baseline
Range
High:58.68%
Low:-38.81%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -1.35% |
| Q2 2025 | 9.14% |
| Q1 2025 | 26.30% |
| Q4 2024 | -10.84% |
| Q3 2024 | -3.87% |
| Q2 2024 | 2.59% |
| Q1 2024 | -0.34% |
| Q4 2023 | 2.94% |
| Q3 2023 | -6.50% |
| Q2 2023 | -7.99% |
| Q1 2023 | -1.64% |
| Q4 2022 | -4.14% |
| Q3 2022 | -0.28% |
| Q2 2022 | -1.68% |
| Q1 2022 | 20.43% |
| Q4 2021 | -11.15% |
| Q3 2021 | -9.63% |
| Q2 2021 | 15.30% |
| Q1 2021 | 7.87% |
| Q4 2020 | 3.22% |
| Q3 2020 | 58.68% |
| Q2 2020 | -38.81% |
| Q1 2020 | 7.24% |
| Q4 2019 | 17.66% |
| Q3 2019 | 5.84% |
| Q2 2019 | -10.25% |
| Q1 2019 | 3.96% |
| Q4 2018 | 13.59% |
| Q3 2018 | -9.50% |
| Q2 2018 | 6.65% |
| Q1 2018 | 9.61% |
| Q4 2017 | 10.73% |
| Q3 2017 | -14.44% |
| Q2 2017 | -17.17% |
| Q1 2017 | 47.25% |
| Q4 2016 | 5.08% |
| Q3 2016 | 10.08% |
| Q2 2016 | -10.55% |
| Q1 2016 | 15.57% |
| Q4 2015 | 12.13% |